Tekijähaun tulokset

1

Chronic Lung Disease after Premature Birth Tekijä Vivek Subbiah

Julkaistu 2008

Hae kokoteksti
Carta

Lisää suosikkeihin

Tallennettuna:
2

The next generation of evidence-based medicine Tekijä Vivek Subbiah

Julkaistu 2023

Hae kokoteksti Hae kokoteksti
Revisão

Lisää suosikkeihin

Tallennettuna:
3

Tissue-agnostic cancer therapies: promise, reality, and the path forward Tekijä Vivek Subbiah

Julkaistu 2025

Hae kokoteksti
Artigo

Lisää suosikkeihin

Tallennettuna:
4

Challenging Standard-of-Care Paradigms in the Precision Oncology Era Tekijä Vivek Subbiah, Razelle Kurzrock

Julkaistu 2018

Hae kokoteksti Hae kokoteksti
Revisão

Lisää suosikkeihin

Tallennettuna:
5

Managing Cancer Care during the COVID-19 Pandemic and Beyond Tekijä Omar Alhalabi, Vivek Subbiah

Julkaistu 2020

Hae kokoteksti Hae kokoteksti
Artigo

Lisää suosikkeihin

Tallennettuna:
6

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis Tekijä Vivek Subbiah, Razelle Kurzrock

Julkaistu 2023

Hae kokoteksti
Artigo

Lisää suosikkeihin

Tallennettuna:
7

Tumor-agnostic drug development in dMMR/MSI-H solid tumors Tekijä Deepak Bhamidipati, Vivek Subbiah

Julkaistu 2023

Hae kokoteksti Hae kokoteksti
Revisão

Lisää suosikkeihin

Tallennettuna:
8

Clinical development and management of adverse events associated with FGFR inhibitors Tekijä Vivek Subbiah, Srđan Verstovšek

Julkaistu 2023

Hae kokoteksti Hae kokoteksti
Revisão

Lisää suosikkeihin

Tallennettuna:
9

Advances in Targeting RET-Dependent Cancers Tekijä Vivek Subbiah, Gilbert J. Cote

Julkaistu 2020

Hae kokoteksti
Revisão

Lisää suosikkeihin

Tallennettuna:
10

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy Tekijä Mohamed A. Gouda, Vivek Subbiah

Julkaistu 2023

Hae kokoteksti
Revisão

Lisää suosikkeihin

Tallennettuna:
11

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors Tekijä Mohamed A. Gouda, Vivek Subbiah

Julkaistu 2023

Hae kokoteksti Hae kokoteksti
Revisão

Lisää suosikkeihin

Tallennettuna:
12

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers Tekijä Mohamed A. Gouda, Vivek Subbiah

Julkaistu 2023

Hae kokoteksti Hae kokoteksti
Revisão

Lisää suosikkeihin

Tallennettuna:
13

Clinical Development of BRAF plus MEK Inhibitor Combinations Tekijä Vivek Subbiah, Christina S. Baik, John M. Kirkwood

Julkaistu 2020

Hae kokoteksti Hae kokoteksti
Revisão

Lisää suosikkeihin

Tallennettuna:
14

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm Tekijä Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Julkaistu 2020

Hae kokoteksti Hae kokoteksti
Revisão

Lisää suosikkeihin

Tallennettuna:
15

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives Tekijä Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

Julkaistu 2017

Hae kokoteksti Hae kokoteksti
Artigo

Lisää suosikkeihin

Tallennettuna:
16

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians Tekijä Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

Julkaistu 2020

Hae kokoteksti
Editorial

Lisää suosikkeihin

Tallennettuna:
17

State-of-the-Art Strategies for Targeting RET-Dependent Cancers Tekijä Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

Julkaistu 2020

Hae kokoteksti
Revisão

Lisää suosikkeihin

Tallennettuna:
18

The abscopal effect in patients with cancer receiving immunotherapy Tekijä Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

Julkaistu 2023

Hae kokoteksti Hae kokoteksti
Revisão

Lisää suosikkeihin

Tallennettuna:
19

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? Tekijä Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

Julkaistu 2025

Hae kokoteksti
Revisão

Lisää suosikkeihin

Tallennettuna:
20

The emerging role of PI3K inhibitors for solid tumour treatment and beyond Tekijä Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Julkaistu 2023

Hae kokoteksti
Revisão

Lisää suosikkeihin

Tallennettuna:

Chronic Lung Disease after Premature Birth Tekijä Vivek Subbiah

The next generation of evidence-based medicine Tekijä Vivek Subbiah

Tissue-agnostic cancer therapies: promise, reality, and the path forward Tekijä Vivek Subbiah

Challenging Standard-of-Care Paradigms in the Precision Oncology Era Tekijä Vivek Subbiah, Razelle Kurzrock

Managing Cancer Care during the COVID-19 Pandemic and Beyond Tekijä Omar Alhalabi, Vivek Subbiah

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i> Tekijä Vivek Subbiah, Razelle Kurzrock

Tumor-agnostic drug development in dMMR/MSI-H solid tumors Tekijä Deepak Bhamidipati, Vivek Subbiah

Clinical development and management of adverse events associated with FGFR inhibitors Tekijä Vivek Subbiah, Srđan Verstovšek

Advances in Targeting RET-Dependent Cancers Tekijä Vivek Subbiah, Gilbert J. Cote

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy Tekijä Mohamed A. Gouda, Vivek Subbiah

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors Tekijä Mohamed A. Gouda, Vivek Subbiah

Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers Tekijä Mohamed A. Gouda, Vivek Subbiah

Clinical Development of BRAF plus MEK Inhibitor Combinations Tekijä Vivek Subbiah, Christina S. Baik, John M. Kirkwood

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm Tekijä Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives Tekijä Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians Tekijä Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers Tekijä Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

The abscopal effect in patients with cancer receiving immunotherapy Tekijä Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? Tekijä Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

The emerging role of PI3K inhibitors for solid tumour treatment and beyond Tekijä Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Hakutulokset - Vivek Subbiah

Chronic Lung Disease after Premature Birth Tekijä Vivek Subbiah

The next generation of evidence-based medicine Tekijä Vivek Subbiah

Tissue-agnostic cancer therapies: promise, reality, and the path forward Tekijä Vivek Subbiah

Challenging Standard-of-Care Paradigms in the Precision Oncology Era Tekijä Vivek Subbiah, Razelle Kurzrock

Managing Cancer Care during the COVID-19 Pandemic and Beyond Tekijä Omar Alhalabi, Vivek Subbiah

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i> Tekijä Vivek Subbiah, Razelle Kurzrock

Tumor-agnostic drug development in dMMR/MSI-H solid tumors Tekijä Deepak Bhamidipati, Vivek Subbiah

Clinical development and management of adverse events associated with FGFR inhibitors Tekijä Vivek Subbiah, Srđan Verstovšek

Advances in Targeting RET-Dependent Cancers Tekijä Vivek Subbiah, Gilbert J. Cote

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy Tekijä Mohamed A. Gouda, Vivek Subbiah

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors Tekijä Mohamed A. Gouda, Vivek Subbiah

Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers Tekijä Mohamed A. Gouda, Vivek Subbiah

Clinical Development of BRAF plus MEK Inhibitor Combinations Tekijä Vivek Subbiah, Christina S. Baik, John M. Kirkwood

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm Tekijä Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives Tekijä Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians Tekijä Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers Tekijä Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

The abscopal effect in patients with cancer receiving immunotherapy Tekijä Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? Tekijä Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

The emerging role of PI3K inhibitors for solid tumour treatment and beyond Tekijä Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Työkalut:

Liittyvät aiheet